the validity of an in vitro clonogenic drug sensitivity assay to predict the induction and the duration of complete remission was evaluated in a group of 81 patients with acute myelogenous leukemia treated with chemotherapy including an anthracycline drug ( daunorubicin or adriamycin ) and cytosine arabinoside ( ara-c ) .
C0023467
acute myelogenous leukemia
C0011015
daunorubicin